Canada markets closed
  • S&P/TSX

    19,078.64
    -144.10 (-0.75%)
     
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • DOW

    31,029.31
    +82.32 (+0.27%)
     
  • CAD/USD

    0.7755
    -0.0014 (-0.18%)
     
  • CRUDE OIL

    109.30
    -2.46 (-2.20%)
     
  • BTC-CAD

    26,201.39
    -60.50 (-0.23%)
     
  • CMC Crypto 200

    438.70
    -0.96 (-0.22%)
     
  • GOLD FUTURES

    1,820.60
    -0.60 (-0.03%)
     
  • RUSSELL 2000

    1,719.37
    -19.47 (-1.12%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • NASDAQ

    11,177.89
    -3.65 (-0.03%)
     
  • VOLATILITY

    28.12
    -0.24 (-0.85%)
     
  • FTSE

    7,312.32
    -11.09 (-0.15%)
     
  • NIKKEI 225

    26,804.60
    -244.87 (-0.91%)
     
  • CAD/EUR

    0.7424
    +0.0088 (+1.20%)
     

Corcept Therapeutics (NASDAQ:CORT) sheds 16% this week, as yearly returns fall more in line with earnings growth

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

It might be of some concern to shareholders to see the Corcept Therapeutics Incorporated (NASDAQ:CORT) share price down 26% in the last month. But that doesn't change the fact that the returns over the last three years have been pleasing. After all, the share price is up a market-beating 76% in that time.

While the stock has fallen 16% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

View our latest analysis for Corcept Therapeutics

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During three years of share price growth, Corcept Therapeutics achieved compound earnings per share growth of 17% per year. We don't think it is entirely coincidental that the EPS growth is reasonably close to the 21% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. Au contraire, the share price change has arguably mimicked the EPS growth.

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

earnings-per-share-growth
earnings-per-share-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. Dive deeper into the earnings by checking this interactive graph of Corcept Therapeutics' earnings, revenue and cash flow.

A Different Perspective

Although it hurts that Corcept Therapeutics returned a loss of 7.3% in the last twelve months, the broader market was actually worse, returning a loss of 10%. Of course, the long term returns are far more important and the good news is that over five years, the stock has returned 12% for each year. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. It's always interesting to track share price performance over the longer term. But to understand Corcept Therapeutics better, we need to consider many other factors. For example, we've discovered 1 warning sign for Corcept Therapeutics that you should be aware of before investing here.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting